GT Biopharma, Inc.

GT Biopharma is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics using proprietary fusion protein platforms called TriKEs (Tri-specific Killer Engagers) and Tetra-specific molecules that activate a patient's natural killer cells to target and eliminate cancer cells expressing specific antigens such as B7-H3, HER2, CD33, and PD-L1 across hematologic malignancies and solid tumors. The company's lead program targets acute myeloid leukemia and myelodysplastic syndrome, while additional candidates address advanced solid tumors and autoimmune disorders; the company believes its NK cell-activating approach may offer safety advantages over T-cell immunotherapy, including reduced cytokine release syndrome and fewer neurological side effects. GT Biopharma holds exclusive worldwide rights to TriKE technology from the University of Minnesota, outsources all manufacturing to contract manufacturers, and generates value through development and potential commercialization of its therapeutic candidates.